HomeDiscoveryPipeline

Pipeline

L’attuale portfolio delle molecole di Nerviano Medical Sciences comprende composti antitumorali in fase clinica o in avanzato stadio di sviluppo preclinico, oltre ai progetti di ricerca.
Diversi programmi sono condotti nell'ambito di alleanze strategiche.

ENCORAFENIB
PRECLINICAL PHASE I PHASE II PHASE III
99% PHASE III
ENTRECTINIB
PRECLINICAL PHASE I PHASE II PHASE III
72% PHASE II
MILCICLIB
PRECLINICAL PHASE I PHASE II PHASE III
62% PHASE II
ONVANSERTIB
(PCM-075 NMS-P937, PLK1)
PRECLINICAL PHASE I PHASE II PHASE III
50% PHASE I
S81694
(NMS-P153, MPS1)
PRECLINICAL PHASE I PHASE II PHASE III
37% PHASE I
ADC-Payload
(NMS-P945)
PRECLINICAL PHASE I PHASE II PHASE III
12% PRECLINICAL
ADC-Payload
(PNU-652)
PRECLINICAL PHASE I PHASE II PHASE III
12% PRECLINICAL
 
PRECLINICAL PHASE I PHASE II PHASE III
DANUSERTIB
(AURORA)
PRECLINICAL PHASE I PHASE II PHASE III
50% PHASE I
NMS-P088
(FLT3, KIT, CSF1R)
PRECLINICAL PHASE I PHASE II PHASE III
25% PRECLINICAL
NMS-P293
(PARP1)
PRECLINICAL PHASE I PHASE II PHASE III
18% PRECLINICAL
ADC-PAYLOAD
platform
PRECLINICAL PHASE I PHASE II PHASE III
12% PRECLINICAL
DISCOVERY programs:
PRECLINICAL PHASE I PHASE II PHASE III
• PC development
PRECLINICAL PHASE I PHASE II PHASE III
12% PRECLINICAL
• Pre-PC
PRECLINICAL PHASE I PHASE II PHASE III
12% PRECLINICAL
• Lead optimization
PRECLINICAL PHASE I PHASE II PHASE III
12% PRECLINICAL
• Early projects
PRECLINICAL PHASE I PHASE II PHASE III
12% PRECLINICAL